Analysts Expect BKMC To Hit $123

Analysts project a 12.91% upside for the BNY Mellon US Mid Cap Core Equity ETF (BKMC), with an implied target price of $122.75 based on the weighted average 12-month forward targets of its underlying holdings. This potential upside is significantly influenced by key constituents such as Roivant Sciences (ROIV), Axalta Coating Systems (AXTA), and Brinker International (EAT), which analysts anticipate will see upsides of 36.36%, 32.05%, and 31.15% respectively, from their recent trading prices.

Analysis

An analysis of the BNY Mellon US Mid Cap Core Equity ETF (BKMC) reveals a significant divergence between its recent trading price and the consensus analyst outlook for its underlying holdings. The ETF's implied 12-month target price of $122.75 suggests a potential upside of 12.91% from its current price of $108.71. This forecast is heavily influenced by a few key constituents with particularly bullish analyst targets. Notably, Roivant Sciences (ROIV), Axalta Coating Systems (AXTA), and Brinker International (EAT) are projected to have substantial upsides of 36.36%, 32.05%, and 31.15%, respectively. While these figures present a compelling quantitative case for the ETF, the analysis is accompanied by a tone of uncertainty, questioning whether these targets are overly optimistic or if analysts are lagging behind recent developments. The large gap between current prices and target prices represents both a potential opportunity if the market is undervaluing these mid-cap names, and a risk if the analyst targets prove to be relics of past optimism and are subject to future downgrades.

Key Decisions for Investors

• Investors bullish on the US mid-cap sector could view the 12.91% implied upside in BKMC as a potential entry point, but should acknowledge this is based on forward-looking analyst consensus, not guaranteed returns.